Baijin Life Science Unit Sets Framework Deal to Grow Medical Business; Shares Lose 2%

MT Newswires Live
12/02

Baijin Life Science (HKG:1466) said its unit, Beijing Baijin Biotechnology, signed a cooperation framework agreement with Shanghai Guhuan Medical Equipment to support the expansion of its medical products business, according to a Monday Hong Kong bourse filing.

Shares of the company were down nearly 2% in Tuesday morning trade.

Under the framework, Beijing Baijin plans to invest in Guhuan Medical through an equity subscription and work with the company to develop branded medical product sales channels for Baijin's self-operated stores.

The agreement runs through Dec. 31, 2026, and may be terminated by either party with 10 days' notice.

Guhuan Medical has operated in the medical-product supply chain for more than a decade and holds stakes in over 30 medical cosmetic institutions, the filing said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10